Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients

July 24, 2026 updated by: Clinuvel Europe Limited

A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients With Erythropoietic Protoporphyria (EPP)

The purpose of this study is to evaluate the concentration of afamelanotide in serum after the administration of afamelanotide in adolescent and adult EPP patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

28

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • EPP patients aged between 12 and 70 years
  • BMI between 15 and 30 kg/m2
  • >50 kg

Exclusion Criteria:

  • Any personal or direct family history of melanoma
  • Any significant history of allergy and/or sensitivity to any of the contents of study drug product or lignocaine or other local anaesthetics if used
  • Any significant illness during the four weeks before the study screening period
  • Any evidence of hepatic or renal impairment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Afamelanotide 16 mg implant
Drug: Afamelanotide 16mg implant
afamelanotide 16mg implant will be administered to each patient during the study.
Other Names:
  • SCENESSE®

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cmax (Maximum Plasma Concentration)
Time Frame: Baseline to Day 7
Blood samples will be collected for analysis of afamelanotide plasma concentrations and understand what the maximum concentration in plasma is.
Baseline to Day 7
AUC(0-t) (Area Under the Curve From Administration to Last Observed Concentration at Time t)
Time Frame: Baseline to Day 7
Blood samples will be collected for analysis of afamelanotide plasma concentrations.
Baseline to Day 7

Secondary Outcome Measures

Outcome Measure
Time Frame
AUC(0-∞) (Area Under the Curve Extrapolated to Infinite Time)
Time Frame: Baseline to Day 7
Baseline to Day 7

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Clinuvel Europe Limited

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 7, 2024

Primary Completion (Actual)

October 28, 2024

Study Completion (Actual)

January 20, 2025

Study Registration Dates

First Submitted

April 4, 2024

First Submitted That Met QC Criteria

April 24, 2024

First Posted (Actual)

April 29, 2024

Study Record Updates

Last Update Posted (Actual)

July 27, 2026

Last Update Submitted That Met QC Criteria

July 24, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CUV052

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe